Pure Global AI
NCT06268210Not yet recruiting

Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer

Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer (NeoLazer): a Phase II, Randomized, Multi-center Study
Yonsei UniversityPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-small Cell Lung Cancer
Drug/Device/Intervention
Lazertinib+Pemetrexed+Carboplatin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Yonsei University
Location
Seoul, South Korea
Timeline & enrollment
Phase
Phase 2
Start date
Mar 01, 2024
End date
Jun 01, 2028
Enrollment
160 participants
Primary outcome

Primary pathological response

Summary

In the randomized, multicenter Phase II clinical trial, we aim to evaluate the efficacy and
 safety of Lazertinib monotherapy or the combination of Lazertinib and cytotoxic chemotherapy
 as neoadjuvant therapy in patients with resectable, treatment-naive EGFR-mutant (exon 19
 deletion or exon 21 L858R) non-small cell lung cancer, ranging from clinical stage IB to
 IIIB. The study is designed to assess the impact on pathological response, as well as
 effectiveness and safety considerations.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06268210
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06268210 through Pure Global AI's free database. This Phase 2 trial is sponsored by Yonsei University and is currently Not yet recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 160 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.